• Login
  • Register
Nairametrics
  • Home
  • Exclusives
    • Recapitalization
      • Access Holdings Offer
      • Fidelity Bank Offer
      • GTCO Offer
      • Zenith Bank Offer
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Nairalytics
  • Economy
    • Business News
    • Budget
    • Public Debt
    • Tax
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Public Offer & Right Issues
      • Stock Market News
    • Fixed Income
    • Funds Management
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Market Views
    • Op-Eds
    • Research Analysis
  • Home
  • Exclusives
    • Recapitalization
      • Access Holdings Offer
      • Fidelity Bank Offer
      • GTCO Offer
      • Zenith Bank Offer
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Nairalytics
  • Economy
    • Business News
    • Budget
    • Public Debt
    • Tax
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Public Offer & Right Issues
      • Stock Market News
    • Fixed Income
    • Funds Management
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Market Views
    • Op-Eds
    • Research Analysis
Nairametrics
Home Companies Company News

Why 2017 was a tough year for Glaxosmithkline Nigeria

Onome Ohwovoriole by Onome Ohwovoriole
March 23, 2018
in Company News, Stock Market
Why 2017 was a tough year for Glaxosmithkline  Nigeria

L-R: Non Executive Director, GlaxoSmithKline Consumer Nigeria Plc (GSK), Mr. Samuel Kuye; Managing Director, GSK, Mr. Dayanand Thandalam Spiral; Chairman, GSK, Mr. Edmund Onuzo; and Company Secretary, Uche Uwechia, during the 45th Annual General Meeting & Extra ordinary General Meeting

Share on FacebookShare on TwitterShare on Linkedin

GlaxoSmithKline Consumer Nigeria Plc yesterday released its financial statements for the year ended December 2017. While revenue increased from ₦14.3 billion in 2016 to ₦16.0 billion in 2017, gross profit fell sharply from ₦8.9 billion in 2016 to ₦4.4 billion in 2017.

Profit before tax increased from ₦185 million in 2016 to ₦1.1 billion in 2017. Profit after tax, however, fell sharply from ₦2.3 billion in 2016 to ₦486 million in 2017.

Despite the sharp fall in profit, the company has opted to pay a special dividend of ₦7.10 from its retained earnings and ₦0.40 dividend from the retained portion of the pioneer earning balance.

MoreStories

Stock chart movement

All-Share Index declines for fourth straight trading day, loses 193,000-mark 

February 27, 2026
Daraju Industries returns to market with N5 billion Series 3 commercial paper 

Daraju Industries returns to market with N5 billion Series 3 commercial paper 

February 27, 2026

Cost of Sales up by over 100%

The company’s cost of sales jumped massively from ₦5.4 billion in 2016 to ₦11.6 billion in 2017. While overhead costs dropped sharply from ₦930million in 2016 to ₦154 million in 2017, materials consumed jumped from ₦4.4 billion in 2016 to ₦11.3 billion in 2017.

This led to the company’s operating segments of consumer healthcare and pharmaceuticals making losses of ₦701 million and ₦15.5 million respectively in 2017.

Investment income saved the day

But for the huge spike in investment income, the company would most likely have made a loss in 2017. Investment income rose from ₦171 million in 2016 to ₦1.1 billion in 2017. This was driven largely by interest on short-term deposits. Interest rates spiked in 2017 in tandem with rising inflation and an increase in government borrowing.

GlaxoSmithKline Consumer Nigeria Plc was incorporated in 1971. 46.1 % of its issued shares are held by GlaxoSmithKline United Kingdom and the rest by Nigerian shareholders. The principal activities of the company are manufacturing, marketing and distribution of consumer healthcare and pharmaceutical products.

 

 

 


Add Nairametrics on Google News
Follow us for Breaking News and Market Intelligence.
Tags: 2017 FY resultsGSK PlcQuickTakes
Onome Ohwovoriole

Onome Ohwovoriole

Onome Ohwovoriole has a degree in Economics and Statistics from the University of Benin and prior to joining Nairametrics in December 2016 as Lead Analyst had stints in Publishing, Automobile Services, Entertainment and Leadership Training. He covers companies in the Nigerian corporate space, especially those listed on the Nigerian Stock Exchange (NSE). He also has a keen interest in new frontiers like Cryptocurrencies and Fintech. In his spare time, he loves to read books on finance, fiction as well as keep up with happenings in the world of international diplomacy. You can contact him via onome.ohwovoriole@nairametrics.com

Next Post

Comments 2

  1. Anonymous says:
    March 25, 2018 at 3:39 pm

    Please can someone kindly explain to me the different between special dividend and ordinary dividend, just wants to know because GSK plc said dey are giving N7.10 as special dividend and 0.40k as ordinary dividend.

    Reply
    • Nairametrics says:
      March 25, 2018 at 10:57 pm

      A Special dividend is one that is issued by a company out of profits it made from Extra-ordinary income. Extra-Ordinary income refers to an income that a business makes upon unusual circumstances. In this case, GSK sold its Drinks Business, so it is the profit it made from that sale that it is sharing to its shareholders.

      Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

rabafast

nairametrics








DUNS

Follow us on social media:

  • HOME
  • ABOUT NAIRAMETRICS
  • CONTACT US
  • DISCLAIMER
  • ADs DISCLAIMER
  • COPYRIGHT INFRINGEMENT

© 2026 Nairametrics

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Social Media Auto Publish Powered By : XYZScripts.com
No Result
View All Result
  • Home
  • Exclusives
    • Recapitalization
      • Access Holdings Offer
      • Fidelity Bank Offer
      • GTCO Offer
      • Zenith Bank Offer
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Nairalytics
  • Economy
    • Business News
    • Budget
    • Public Debt
    • Tax
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Public Offer & Right Issues
      • Stock Market News
    • Fixed Income
    • Funds Management
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Market Views
    • Op-Eds
    • Research Analysis
  • Login
  • Sign Up

© 2026 Nairametrics